| Product name | Target | Indications | Stages |
|---|---|---|---|
| EDP1066 | N/A | ||
| EDP1503 | N/A | ||
| EDP1815 | N/A |
| $ in millions | 2016 | 2017 |
|---|---|---|
| Gut-body network platform expenses | $2.1 | $3.8 |
| Inflammation programs | $0.0 | $4.3 |
| Oncology programs | $2.6 | $3.7 |
| Other program expenses | $0.4 | $0.6 |
| R&D personnel | $4.1 | $7.6 |
| Total R&D spend | $9.1 | $20.0 |
| G&A spend | $3.9 | $7.8 |
| Operating income / loss | -$13.0 | -$27.7 |
| Licensor | Date | Initial cash | Total milestones | Min royalty | Max royalty |
|---|---|---|---|---|---|
| University of Chicago | 03/01/2016 | Less than $500,000 | $60.9 | Low single-digit | Low single-digit |
| Mayo Clinic | 08/01/2017 | $0.2 | $56.0 | Low single-digit | Low single-digit |
| Round | Date | Amount | Post-money | Returns at IPO | Investors |
|---|---|---|---|---|---|
| Series A | 06/29/2015 | $7.0 | $10.5 | 6.5x | Flagship |
| Series A1 | 06/16/2016 | $6.1 | $16.6 | 6.5x | Flagship |
| Series A2 | 06/13/2016 | $7.0 | $40.2 | 3.3x | Flagship |
| Series A3 | 06/16/2016 | $10.5 | $50.7 | 3.3x | Flagship |
| Series B | 01/05/2017 | $50.5 | $126.5 | 2.2x | Flagship, GV, Celgene, Mayo Clinic, Alexandria Venture Investments, |
| Series C | 02/09/2018 | $81.5 | $308.4 | 1.2x | Flagship, Fidelity, GV, Celgene, Mayo Clinic, Alexandria Venture Investments, |